Compare iShares MSCI Japan ETF (EWJ) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Incyte Corporation — how do they compare? iShares MSCI Japan ETF trades at $91.93, while Incyte Corporation trades at $116.15 (market cap $22.99B). The key difference: Incyte Corporation is trading nearer its 52-week high, iShares MSCI Japan ETF nearer its low. Which is the better fit depends on your goals.
| EWJ | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $118.52 |
52-Week Low | $71.81 | $67.38 |
Market Cap | — | $22.99B |
Enterprise Value | — | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $91.98, down 2.03% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Key support lies at $92-$93 and resistance at $94-$95. Recent news highlights Japan's market dynamics, including currency intervention risks and pension fund shifts.
The ETF offers exposure to Japanese equities amid a weakening yen and potential government support. Risks include yen volatility and economic sensitivity. Analyst sentiment is mixed, with technical strength offset by currency and macroeconomic uncertainties.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
